36. Epidermolysis bullosa Clinical trials / Disease details

Clinical trials : 163 / Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05651607 (ClinicalTrials.gov)	January 2023	7/12/2022	Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa	Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa	Hereditary Epidermolysis Bullosa	Drug: Cannabidiol	Assistance Publique - Hôpitaux de Paris	HELEBOR;Fondation Apicil;Lions Club International Foundation	Not yet recruiting	2 Years	17 Years	All	10	Phase 2	France
2	NCT04613102 (ClinicalTrials.gov)	August 1, 2020	27/10/2020	The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial	The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial	Epidermolysis Bullosa;Pain;Itch	Drug: AVCN583601 (3% Cannabidiol cream)	Elena Pope	Avicanna Inc	Withdrawn	4 Years	50 Years	All	0	Phase 2/Phase 3	Canada
3	EUCTR2021-000103-20-NL (EUCTR)		15/07/2021	A study on the effect of Transvamix on pain in adults with epidermolysis bullosa.	An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa	Genetic Epidermolysis Bullosa;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]	Product Name: Transvamix (100mg/mL THC, 50mg/mL CBD) INN or Proposed INN: THC Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL INN or Proposed INN: CBD Other descriptive name: CANNABIDIOL	University Medical Center Groningen	NULL	NA			Female: yes Male: yes	16	Phase 2	Netherlands